Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,021 - 1,040 results of 18,229 for search 'significantly ((((linear decrease) OR (((a decrease) OR (nn decrease))))) OR (greater decrease))', query time: 0.48s Refine Results
  1. 1021
    Image 2_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg

    Image 2_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

    Published 2025
    Save to List
    Saved in:
  2. 1022
    Image 1_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg

    Image 1_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

    Published 2025
    Save to List
    Saved in:
  3. 1023
    Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  4. 1024
    Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  5. 1025
    Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  6. 1026
    Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  7. 1027
    Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  8. 1028
    Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  9. 1029
    Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  10. 1030
    Disruption of the <i>pcnB</i> gene encoding poly(A) polymerase PAP I decreases pYV PCN as well as T3SS expression and activity.

    Disruption of the <i>pcnB</i> gene encoding poly(A) polymerase PAP I decreases pYV PCN as well as T3SS expression and activity. by Katherine Schubert (5452712)

    Published 2025
    Save to List
    Saved in:
  11. 1031
    Supplementary file 1_Global variation in antibiotic prescribing guidelines and the implications for decreasing AMR in the future.docx

    Supplementary file 1_Global variation in antibiotic prescribing guidelines and the implications for decreasing AMR in the future.docx by Emmama Jamil (22005635)

    Published 2025
    Save to List
    Saved in:
  12. 1032
    The influence of <i>PINK1</i> on <i>P</i>. <i>berghei</i> infection in <i>A</i>. <i>stephensi</i>.

    The influence of <i>PINK1</i> on <i>P</i>. <i>berghei</i> infection in <i>A</i>. <i>stephensi</i>. by Li Gao (131516)

    Published 2024
    Save to List
    Saved in:
  13. 1033
    RipU<sup>K60</sup> decreases microtubule abundance at 48 hours post infiltration.

    RipU<sup>K60</sup> decreases microtubule abundance at 48 hours post infiltration. by Rachel Hiles (20477573)

    Published 2024
    “…(B) Heterologous expression of RipU<sup>K60</sup> significantly decreased microtubule number compared to controls at 48 hpi in <i>N</i>. …”
    Save to List
    Saved in:
  14. 1034
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1035
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1036
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1037
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1038
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1039
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1040
    Evolution of the four pre-stimuli psychological parameters (A: Valence, B: Arousal, C: Tension, D: Energy).

    Evolution of the four pre-stimuli psychological parameters (A: Valence, B: Arousal, C: Tension, D: Energy). by Felix Alexandre Schoeller (20988295)

    Published 2025
    Save to List
    Saved in:

Search Tools: